Challenges in the Management of Relapsed/Refractory Multiple Myeloma

In this episode, experts explore the major barriers that accompany therapeutic progress in relapsed or refractory multiple myeloma. Panelists first emphasize that access remains a central challenge. Although innovative treatments deliver strong outcomes, availability varies widely, creating inequities for patients who live far from major cancer centers. Experts note that caregivers also face uncertainty in managing new toxicities, highlighting the need for broader education and support. From a provider standpoint, the discussion stresses the importance of training community clinicians so that advanced therapies can be delivered closer to home. Panelists also describe the institutional commitment required, including round-the-clock availability and dedicated clinic resources, which are not universal across treatment settings. Financial burdens further complicate access, even when infrastructure is in place. As the conversation transitions toward bispecific antibodies, experts point out that these therapies may expand treatment opportunities for patients lacking access to CAR T options.